Bookrunners Jefferies and RBC Capital Markets to assist with offering
By Devika Patel
Knoxville, Tenn., Nov. 6 – Marinus Pharmaceuticals, Inc. said it priced a $30 million public sale of stock with a $4.5 million greenshoe. The offering was announced Thursday.
The company will sell 5 million common shares at $6.00 per share. The price per share reflects a 22.38% discount to the Nov. 5 closing share price of $7.73.
Jefferies LLC and RBC Capital Markets, LLC are the bookrunners.
Settlement is expected Nov. 12.
Proceeds will be used for preclinical and clinical development of ganaxolone, including trials, regulatory, research and development, pre-commercial, general and administrative and manufacturing expenses and working capital and general corporate purposes.
The biopharmaceutical company is based in New Haven, Conn.
| Issuer: | Marinus Pharmaceuticals, Inc.
|
| Issue: | Common stock
|
| Amount: | $30 million
|
| Greenshoe: | $4.5 million, or 750,000 shares
|
| Shares: | 5 million
|
| Price: | $6.00
|
| Warrants: | No
|
| Bookrunners: | Jefferies LLC and RBC Capital Markets, LLC
|
| Lead manager: | JMP Securities LLC
|
| Co-manager: | Raymond James & Associates, Inc.
|
| Announcement date: | Nov. 5
|
| Pricing date: | Nov. 6
|
| Settlement date: | Nov. 12
|
| Stock symbol: | Nasdaq: MRNS
|
| Stock price: | $7.73 at close Nov. 5
|
| Market capitalization: | $82.71 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
